Cardiac natriuretic peptides as markers for cardiac disease - Where do we stand today?;Natriuretiske hjertepeptider som markører for hjertesykdom

Tidsskrift for den Norske Laegeforening

Volumn 122, Issue 29, 2002, Pages 2784-2786

  Hall, Christian ^a   Stokke, Oddvar ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; HORMONE PRECURSOR;

ARTICLE; BIOCHEMISTRY; CLINICAL PRACTICE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MARKER; FOLLOW UP; HEART DISEASE; HEART FAILURE; HEART VENTRICLE PRESSURE; HUMAN; MEDICAL LITERATURE; PATIENT MONITORING; PEPTIDE ANALYSIS; PROGNOSIS;

ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HUMANS; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEIN PRECURSORS;

EID: 0037202729     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 1981; 28: 89-94.
2. Rouleau JL, Pfeffer MA, Stewart DJ, Isaac D, Sestier F, Kerut EK et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet 2000; 356: 615-20.
3. Colucci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AD et al. Intravenous Nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med 2000; 343: 246-53.
4. Hall C. Atrialt natriuretisk peptid. En oversikt. Tidsskr Nor Lægeforen 1988; 108: 225-6.
5. Sundsford JA, Thibault G, Larochelle P, Cantin M. Identification and plasma concentration of the N terminal fragment of proatrial natriuretic factor in man. J Clin Endocrinol Metab 1988; 66: 605-10.
6. Mathisen P, Hall C, Simonsen S. A comparative study of atrial peptides ANF(1-98) and ANF(99-126) as diagnostic markers of atrial distension in patients with cardiac disease. Scand J Clin Lab Invest 1993; 53: 41-9.
7. Hall C, Rouleau JL, Moye L, de Champlain J, Bichet D, Klein M et al. N-terminal proatrial natriuretic factor - An important and independent predictor of long term prognosis after myocardial infarction. Circulation 1994; 89: 1934-42.
8. Smiseth OA. Kan hjertesvikt diagnostiseres ved hormonprøve? Tidsskr Nor Lægeforen 1996; 116: 1560-1.
9. Omland T, Aakvaag A, Vik-Mo H. Kardiale natriuretiske peptider som markør for venstre ventrikkel-dysfunksjon. Tidsskr Nor Lægeforen 1997; 117: 943-8.
10. Task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001; 22: 1527-60.
11. Cowie MR, Struthers AD, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997; 350: 1349-53.
12. Hall C, Kjekshus J, Eneroth P, Snapinn S. The plasma concentration of N-terminal proatrial natriuretic factor ANF(1-98) is related to prognosis in severe heart failure. Clin Cardiol 1994; 17: 191-5.
13. de Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001; 345: 1014 -21.
14. Kirk V, Bay M, Hassager C, Nielsen H, Parner J, Herzog T et al. Plasma level of N-terminal-proBrain natriuretic peptide predicts 1 year mortality. Eur J Heart Failure 2000; 2 (suppl 2): 62-3.
15. Wallen T, Landahl S, Hedner T, Hall C, Saito Y, Nakao K. Atrial natriuretic peptides predict mortality in the elderly. J Intern Med 1997; 241: 269-75.
16. McDonagh TA, Cunningham AD, Morrison CE, McMurray JV, Ford I, Morton JJ et al. Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population. Heart 2001; 86: 21-6.
17. Anderson J, Woodruff PWR, Bloom SR. The effect of treatment of congestive heart failure on plasma atrial natriuretic peptide concentration: A longitudinal study. Br Heart J 1988; 59: 207-11.
18. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study (RALES)). Am J Cardiol 1996; 78: 902-7.
19. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Consensus Trial Study Group. Circulation 1990; 82: 1730-6.
20. Klinge R, Polis A, Dickstein K, Hall C. Effects of angiotensin II receptor blockage on N-terminal proatrial natriuretic factor plasma levels in chronic heart failure. J Card Fail 1997; 3: 75-81.
21. Goldstein S, Kennedy HL, Hall C, Anderson JL, Gheorghiade M, Gottlieb S et al. Metoprolol CR/XL in patients with heart failure: A pilot study examining the tolerability, safety, and effect on left ventricular ejection fraction. Am Heart J 1999; 138: 1158-65.
22. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM.Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000; 355: 1126-30.
23. Richards AM, Nicholls MG, Yandle TG, Frampton C, Espiner EA, Turner JG et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: New neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998; 97: 1921-9.
24. Mukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, Ogawa Y et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991; 87: 1402-12.
25. Hystad ME, Geiran OR, Attramadal H, Spurkland A, Vege A, Simonsen S et al. Regional cardiac expression and concentration of natriuretic peptides in patients with severe chronic heart failure. Acta Physiol Scand 2001; 171: 395-403.
26. Qi W, Mathisen P, Kjekshus J, Simonsen S, Bjornerheim R, Endresen K et al. Natriuretic peptides in patients with aortic stenosis. Am Heart J 2001; 142: 725-32.
27. Holmstrom H, Hall C, Stokke O, Thaulow E. Plasma levels of N-terminal proatrial natriuretic peptide in children are dependent on renal function and age. Scand J Clin Lab Invest 2000; 60: 149-59.
28. Berendes E, Walter M, Cullen P, Prien T, Van Aken H, Horsthemke J et al. Secretion of brain natriuretic peptide in patients with aneurysmal subarachnoid haemorrhage. Lancet 1997; 349: 245-9.
29. Johnson BE, Damodaran A, Rushin J, Gross A, Le PT, Chen HC et al. Ectopic production and processing of atrial natriuretic peptide in a small cell lung carcinoma cell line and tumor from a patient with hyponatremia. Cancer 1997; 79: 35-44.
30. Struthers AD. N-terminal proBNP -the most cost effective way to identify post myocardial infarction left ventriular dysfunction? Eur Heart J 2000; 21: 1490-2.